Circulate Health Reveals Study Results on Therapeutic Plasma Exchange and Biological Age Reduction

Circulate Health's Groundbreaking Study on Therapeutic Plasma Exchange

In a recent groundbreaking study published in Aging Cell, Circulate Health has unveiled promising results regarding therapeutic plasma exchange (TPE) and its role in reducing biological age. The study is particularly significant as it highlights the benefits of TPE, showing an average biological age reduction of 2.6 years among participants.

Overview of the Study

Conducted in collaboration with researchers from the Buck Institute for Research on Aging, this single-blind clinical trial marks the first of its kind focused on the effectiveness of TPE as a longevity intervention.
The trial enrolled participants into one of four groups: biweekly TPE, biweekly TPE combined with intravenous immunoglobulin (IVIG), monthly TPE, or a control group. The results indicated that participants receiving biweekly TPE with IVIG experienced the most substantial decrease in biological age, averaging a reduction of 2.61 years compared to 1.32 years for those receiving TPE alone.

Mechanisms of Action

The multi-omics analysis of the study focused on biomarkers associated with biological age, investigating changes across multiple biological systems including the epigenome, proteome, metabolome, glycome, and immune system. This comprehensive analysis provided insights into how TPE affects aging at a molecular level, revealing key changes in immune cell composition and activity.

Patients undergoing TPE with IVIG experienced a rejuvenation of immune cells, suggesting an improvement in the body’s defense against infections and age-associated diseases. It was noted that individuals with indicators of poorer baseline health saw the most significant biological age reductions, demonstrating TPE's potential applicability across diverse demographics.

Treatment Administration and Results

The study’s outcomes showed that while initial TPE sessions yielded the greatest effects, benefits tended to diminish over time, indicating a possible need for treatment spacing or combinations with other therapeutic methods to sustain long-term improvements.
Brad Younggren, CEO of Circulate Health, stated, “The findings from our study support the notion that plasma exchange, especially when paired with IVIG, can significantly affect processes linked to biological aging.” This assertion aligns perfectly with their vision to explore targeted plasma interventions that can actively reshape age-associated molecular alterations.

Future Directions and Implications

Dr. David Furman, the senior author of the study, emphasized the necessity of investigating further practical applications of TPE in the medical field. As plasma exchange technology continues to evolve, Circulate Health is keen to broaden studies to encompass larger populations while identifying key areas where these therapies could significantly impact healthspan.

With an ongoing commitment to revolutionizing age-related healthcare, Circulate Health stands at the forefront of innovative treatments aimed at not just extending lifespan but enhancing the quality of life in later years.

For more information about Circulate Health and its endeavors in age-reversal technologies, visit www.circulate.health.